Dressings which may be useful in disrupting and/or preventing biofilm formation in a wound upon application are described, where the dressings of the present technology include a co-polymer of polyvinylpyrrolidone (PVP) and citric acid. Also disclosed herein methods employing such dressings as well as kits including such dressings.

Methods and compositions for reducing a ratio of collagen III to collagen I in wounded skin, treating wounds and accelerating healing is provided with a surfactant polymer dressing comprising FL2 siRNA, collagen and a poloxamer.

An article. The article includes more than 50 wt % collagen matrix, wherein the collagen matrix has a pH value from 2 to 6; wherein the article is a wound dressing.

Polymeric compositions, methods, and delivery devices for inhibiting bleeding are disclosed. The method includes applying a dried material topically to a wound site, where the material may include a cross-linked biologically compatible polymer which forms a hydrogel when exposed to blood and where the material may not include an active agent such as thrombin. A spring-loaded delivery device as described herein may be used to apply the dried material.

Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived grown factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using dosing procedures leading to effective results with a minimal number of treatment applications are also described.

Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived grown factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using dosing procedures leading to effective results with a minimal number of treatment applications are also described.

The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.

Powdered collagen compositions and methods for wound care or the dressing or treatment of wounds in a subject in need thereof. The powdered collagen wound care composition includes powdered collagen or collagen-based material substantially covered with a hydrophobic barrier. In at least some instances, the hydrophobic barrier prevents the complete absorption or dissolution of the powdered collage or collagen-based material when placed on or in a wound or body of a subject for at least three (3) days. The powdered collagen wound care compositions are suitable for dressing or packing wounds or post-surgical incisions.

Disclosed is a wound treatment that includes collagen and a gelatin-reducing agent. Also disclosed is a wound dressing including a substrate, collagen, and a gelatin-reducing agent. The collagen and gelatin-reducing agent may be present in any suitable a weight ratio relative to one another, such as a weight ratio of about 0.25:1 to about 4:1 with respect to one another. Also disclosed is a method for promoting wound healing including administering collagen and a gelatin-reducing agent to a wound in need of treatment.

Disclosed are compositions derived from non-primate mammals having reduced expression of alpha 1,3 gal and their use in food products, food additives, cosmetic products, cosmetic additives, medical products, medical devices and products used in research and production of therapeutics. The compositions and methods disclosed are particularly useful to subjects diagnosed with α-Gal Syndrome (AGS).